137 related articles for article (PubMed ID: 9083163)
1. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 predicts recurrence and survival among head and neck cancer patients.
Duffy SA; Taylor JM; Terrell JE; Islam M; Li Y; Fowler KE; Wolf GT; Teknos TN
Cancer; 2008 Aug; 113(4):750-7. PubMed ID: 18536030
[TBL] [Abstract][Full Text] [Related]
3. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma.
Heimdal JH; Aarstad HJ; Olofsson J
Laryngoscope; 2000 Mar; 110(3 Pt 1):402-7. PubMed ID: 10718427
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
6. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.
Homer JJ; Greenman J; Drevs J; Marme D; Stafford ND
Head Neck; 2002 Aug; 24(8):773-8. PubMed ID: 12203803
[TBL] [Abstract][Full Text] [Related]
7. Serum prognostic markers in head and neck cancer.
Meyer F; Samson E; Douville P; Duchesne T; Liu G; Bairati I
Clin Cancer Res; 2010 Feb; 16(3):1008-15. PubMed ID: 20103685
[TBL] [Abstract][Full Text] [Related]
8. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock.
Iglesias J; Marik PE; Levine JS;
Am J Kidney Dis; 2003 Jan; 41(1):62-75. PubMed ID: 12500222
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
11. Influence of locoregional radiation treatment on tumor necrosis factor-alpha and interleukin-6 in the serum of patients with head and neck cancer.
Akmansu M; Unsal D; Bora H; Elbeg S
Cytokine; 2005 Jul; 31(1):41-5. PubMed ID: 15878671
[TBL] [Abstract][Full Text] [Related]
12. Effect of education level on outcome of patients treated on Radiation Therapy Oncology Group Protocol 90-03.
Konski A; Berkey BA; Kian Ang K; Fu KK
Cancer; 2003 Oct; 98(7):1497-503. PubMed ID: 14508838
[TBL] [Abstract][Full Text] [Related]
13. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03.
Rabinovitch R; Grant B; Berkey BA; Raben D; Ang KK; Fu KK; Cooper JS;
Head Neck; 2006 Apr; 28(4):287-96. PubMed ID: 16287132
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.
Siddiqui F; Pajak TF; Watkins-Bruner D; Konski AA; Coyne JC; Gwede CK; Garden AS; Spencer SA; Jones C; Movsas B
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):353-60. PubMed ID: 17889449
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
[TBL] [Abstract][Full Text] [Related]
17. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
Lavertu P; Adelstein DJ; Myles J; Secic M
Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
[TBL] [Abstract][Full Text] [Related]
18. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
19. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Chen Z; Malhotra PS; Thomas GR; Ondrey FG; Duffey DC; Smith CW; Enamorado I; Yeh NT; Kroog GS; Rudy S; McCullagh L; Mousa S; Quezado M; Herscher LL; Van Waes C
Clin Cancer Res; 1999 Jun; 5(6):1369-79. PubMed ID: 10389921
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Teknos TN; Cox C; Yoo S; Chepeha DB; Wolf GT; Bradford CR; Carey TE; Fisher SG
Head Neck; 2002 Nov; 24(11):1004-11. PubMed ID: 12410536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
